Page last updated: 2024-10-30

losartan and Biliary Cirrhosis

losartan has been researched along with Biliary Cirrhosis in 2 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Research Excerpts

ExcerptRelevanceReference
"We studied, in rats with secondary biliary cirrhosis and sham-operated rats, the effect of 0."5.33Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis. ( Heller, J; Hennenberg, M; Neef, M; Sauerbruch, T; Schepke, M; Shiozawa, T; Trebicka, J, 2005)
"We studied, in rats with secondary biliary cirrhosis and sham-operated rats, the effect of 0."1.33Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis. ( Heller, J; Hennenberg, M; Neef, M; Sauerbruch, T; Schepke, M; Shiozawa, T; Trebicka, J, 2005)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jazaeri, F1
Afsharmoghaddam, R1
Abdollahi, A1
Ghamami, G1
Dehpour, AR1
Heller, J1
Trebicka, J1
Shiozawa, T1
Schepke, M1
Neef, M1
Hennenberg, M1
Sauerbruch, T1

Other Studies

2 other studies available for losartan and Biliary Cirrhosis

ArticleYear
Evaluation of Chronic Losartan Treatment Effect on Cardiac Chronotropic Dysfunction in Biliary Cirrhotic Rats.
    Acta medica Iranica, 2018, Volume: 56, Issue:1

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Heart Atria; Heart Rate; Ligation; Liver Cirrhosis

2018
Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis.
    Liver international : official journal of the International Association for the Study of the Liver, 2005, Volume: 25, Issue:3

    Topics: Adrenergic alpha-Agonists; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Dose-Response Re

2005